OBJECTIVE: To probe into the effect of volume-based procurement of Amlodipine besylate tablets on application of other calcium channel blockers（ CCB）

so as to provide references for policy making and hospital pharmacy management. METHODS: Pharmacoeconomics method was used to analyze the consumption quantity

consumption sum

defined daily dose（ DDDs） and defined daily cost（ DDC） of CCB drugs in outpatient pharmacy in this hospital before（ from Dec. 22 nd

2018 to Dec. 21 st

2019） and after（ Dec. 22 nd

2019 to Dec. 21 st

2020） the implementation of volume-based procurement; multivariate orderly logistic regression analysis was used to discuss the effect of volume-based procurement of Amlodipine besylate tablets on the application of other CCB. RESULTS: After the implementation of volume-based procurement

the consumption quantity of Amlodipine besylate tablets had increased by 594 tablets（ from 438 200 tablets to 438 794 tablets）

and the proportion of its consumption quantity accounted for the total consumption quantity of CCB drugs had increased by 4. 72%（ from 32. 43% to 37. 15%）; the consumption sum had decreased by 1 478 161. 01 yuan（ from 1 503 026. 00 yuan to 24 864. 99 yuan）

the proportion of its consumption sum accounted for the total consumption sum of CCB drugs had decreased by 34. 73%（ from 35. 80%to 1. 07%）; the DDDs had increased by 0. 14%（ from 438 200 to 438 794）; the DDC had decreased to 0. 06 yuan/day

which was only 0. 02% of before the implementation of volume-based procurement（ 3. 43 yuan/day）. The results of multivariate orderly logistic regression analysis after correcting interference factors showed that the DDDs of Amlodipine besylate tablets had decreased after the implementation of volume-based procurement and the difference was statistically significant（ P < 0. 05）

while had no effect on other CCB drugs. CONCLUSIONS: After the implementation of volume-based procurement of Amlodipine besylate tablets

the DDC of patients has significantly decreased

and it also affects the consumption quantity of other CCB drugs. With the further deepening of medical reform and the normalization and institutionalization of volume-based procurement

the drug prices will be more reasonable and benefit the general public.